AI for Pharma & Healthcare 2025

Circle Biologics introduces single device Autologous Platelet Concentrator Platform

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Philips, Masimo Extend Partnership to Sensor...

Philips and Masimo have gone on to renew their...

Measuring Digital Health Success: KPIs and...

Measuring Success: KPIs and Metrics for Digital Health Initiatives The...

Patient Experience in the Digital Age:...

Patient Experience in the Digital Age: Technology's Role in...

Data-Driven Quality Improvement: Enhancing Patient Outcomes

Data-Driven Quality Improvement: Using Analytics to Enhance Patient Outcomes The...

Circle Biologics®, Inc. has announced a technological break-through in regenerative medicine – its Autologous Platelet Concentrator Platform (APC™).  This innovative single device platform is the first of its kind to incorporate both autologous (patient derived) cell concentration and protein concentration in one point-of-care device.

The APC patented design (which has earned the US Food and Drug Administration’s 510(k) marketing approval from its Office of Cellular, Tissue and Gene Therapies for creation of Platelet Rich Plasma and concentrated Platelet Poor Plasma) is a two-chamber, closed system that allows the user to perform two processing steps without the risk of contamination or waste, typically associated with transferring fluids between devices.

According to Matthew Kyle, president of Circle Biologics, this device will bring significant benefits to the surgical and healing processes associated with Cardiosurgery, Orthopedics, Cosmetic Surgery and Dental care.

"While this is not the first platelet-rich plasma device on the market, it is the first to incorporate both patient derived cell and protein concentration in one," says Kyle.  "It’s a technological advancement in treating the entire medical procedure, giving improved solutions for patients and providers."

With its unique insights to medical care, Circle Biologics is standardizing the process of patient derived, patient point of care bio-fluid and cellular preparation across several therapies (i.e., platelet-rich plasma, stem cell, and tissue enrichment/generation). Additionally, the company has developed solutions that address the entire procedure—from procurement to processing to delivery or implantation—with a streamlined combination of devices that spare cells, reduce outside exposure, and protect the user and recipient.

Latest stories

Related stories

Philips, Masimo Extend Partnership to Sensor Technologies

Philips and Masimo have gone on to renew their...

Measuring Digital Health Success: KPIs and Metrics

Measuring Success: KPIs and Metrics for Digital Health Initiatives The...

Patient Experience in the Digital Age: Tech & Engagement

Patient Experience in the Digital Age: Technology's Role in...

Data-Driven Quality Improvement: Enhancing Patient Outcomes

Data-Driven Quality Improvement: Using Analytics to Enhance Patient Outcomes The...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »